Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness
- Resource Type
- Journal
- Source
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY ; MAY 6 2020, 8p.- Subject
- Language
- English
- ISSN
- 14321912